Assembly Bio公司 EASL 2019 Review PDF - 学术讨论& HBV English

EASL Highlights and Next Steps
• Nucs are effective, but do not eliminate residual HBV DNA and HBV RNA
• Combination of 731+ Nuc demonstrated potential to eliminate residual HBV DNA
• Core Inhibitors have the potential to be the backbone of future HBV regimens
– We believe that elimination of residual viremia will likely be a critical milestone required to increase
rates of cure
• 2158 currently in dose finding Phase 1b study and Phase 2a studies expected to follow
immediately
• 3733 expected to initiate Phase 1a study in early 2020
• Initiating discussions with global regulatory bodies regarding design of next studies and
pathways to approval for 731 + Nuc combination

回复引用

举报返回顶部

newchinabok

元帅

Rank: 10

现金: 20620 元
精华: 7
帖子: 12759
注册时间: 2013-12-29
最后登录: 2024-6-18

9楼

发表于 2019-4-15 21:57 |只看该作者

EASL亮点和下一步
•nucs是有效的，但不能消除残留的HBV DNA和HBV RNA。
•结合731+nuc可消除残留的HBV DNA。
•核心抑制剂有潜力成为未来HBV治疗方案的支柱。
–我们认为，消除残余病毒血症可能是增加
治愈率
•2158目前正在进行剂量发现阶段1b研究和阶段2a研究，预计随后
立即
•3733预计将于2020年初启动第1a阶段研究。
•开始与全球监管机构讨论下一项研究的设计，以及
731+NUC组合的批准途径

回复引用

举报返回顶部

newchinabok

元帅

Rank: 10

现金: 20620 元
精华: 7
帖子: 12759
注册时间: 2013-12-29
最后登录: 2024-6-18

10楼

发表于 2019-4-15 22:12 |只看该作者

本帖最后由 newchinabok 于 2019-4-15 22:13 编辑

Initiating discussions with global regulatory bodies regarding design of next studies and
pathways to approval for 731 + Nuc combination与全球监管机构就731+Nuc组合的下一项研究和批准途径的设计展开讨论。（个人认为fda快速通道上市）

回复引用

GMT+8, 2024-10-3 18:16 , Processed in 0.014265 second(s), 10 queries , Gzip On.

Powered by Discuz! X1.5

关闭 安全验证

Assembly Bio公司 EASL 2019 Review PDF [复制链接]

关闭安全验证